Recombinant Human PCSK9 Protein (Highly Pure) – Research Use Only

Recombinant Human PCSK9 (Highly Pure) is a biotechnology‑grade preparation of the secreted proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a key regulator of receptor turnover and protein trafficking, making this recombinant form a valuable tool for protein–protein interaction studies, receptor‑binding assays, biochemical characterization, and mechanistic research involving regulated protein degradation pathways. The lyophilized format enables flexible reconstitution for in vitro workflows requiring high‑purity PCSK9.

Scientific Overview

PCSK9 is a secreted serine protease family member involved in the regulation of receptor turnover and protein trafficking. After autocatalytic processing, PCSK9 interacts with specific cell‑surface receptors and directs them toward lysosomal degradation. This mechanism makes PCSK9 a widely used model for studying receptor internalization, ligand–receptor interactions, protein quality control, and regulated protein degradation pathways. The highly pure recombinant form is ideal for biochemical and structural studies.

Common Research Applications

• Protein–protein interaction assays
• Receptor‑binding and trafficking studies
• Biochemical and enzymatic characterization
• Structural and biophysical analysis
• Ligand‑binding affinity measurements
• Mechanistic studies of regulated protein turnover

Usage & Handling Guidance

Reconstitute in sterile buffer to the desired concentration. Aliquot immediately after reconstitution to avoid freeze–thaw cycles. Maintain samples on ice during experimental setup and use low‑binding tubes for optimal recovery.

• Storage (lyophilized): -20 °C
• Storage (reconstituted): -80 °C
• Handling: Avoid freeze–thaw cycles; aliquot after reconstitution
• Compatibility: Biochemical assays, receptor‑binding studies, structural workflows

What You Get

• 50 µg Recombinant Human PCSK9 Protein (Highly Pure)
• Lyophilized, biotechnology‑grade preparation
• Batch‑specific documentation available upon request
• For research use only (RUO)

Frequently Asked Questions

• Does this PCSK9 include the prodomain?
  Yes. PCSK9 undergoes autocatalytic processing, and the mature form includes the prodomain associated with the catalytic domain.
• Is this protein suitable for receptor‑binding assays?
  Yes. It is commonly used for in vitro receptor‑binding and interaction studies.
• Can this protein be used for structural biology?
  Yes. The high‑purity recombinant form is compatible with crystallography, cryo‑EM, and biophysical analysis.
• Is this product suitable for diagnostic or therapeutic use?
  No. This reagent is intended strictly for in vitro research use only (RUO).

---

References

• Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy Acta Pharm Sin B. 2021 Apr;11(4):941-960.
• Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira JP, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D; SCARLET Trial Group. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial JAMA. 2019 May 28;321(20):1993-2002.
• Lupo MG, Bressan A, Donato M, Canzano P, Camera M, Poggio P, Greco MF, Garofalo M, De Martin S, Panighel G, Ruscica M, Baragetti A, Bollati V, Faggin E, Rattazzi M, Catapano AL, Ferri N. PCSK9 promotes arterial medial calcification Atherosclerosis. 2022 Apr;346:86-97.
• Annex BH, Cooke JP. New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease Circ Res. 2021 Jun 11;128(12):1944-1957.
• Guo Y, Tang Z, Yan B, Yin H, Tai S, Peng J, Cui Y, Gui Y, Belke D, Zhou S, Zheng XL. PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):67-86.
• Wang M, Zhao D, Xu L, Guo W, Nie L, Lei Y, Long Y, Liu M, Wang Y, Zhang X, Zhang L, Li H, Zhang J, Yuan D, Yue L. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome Metabolism. 2019 May;94:47-58.
• Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, Mayer G. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2517-25.
• Scalise V, Sanguinetti C, Neri T, Cianchetti S, Lai M, Carnicelli V, Celi A, Pedrinelli R. PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling Int J Mol Sci. 2021 Nov 23;22(23):12640.
• Ding Z, Wang X, Liu S, Shahanawaz J, Theus S, Fan Y, Deng X, Zhou S, Mehta JL. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy Cardiovasc Res. 2018 Nov 1;114(13):1738-1751.